Imugene's significant R&D tax refund

Imugene (ASX:IMU) has announced the pending receipt of an $11 million R&D tax refund for the 2023 financial year. This refund comes from the Australian Government's R&D tax incentive, providing a refundable tax offset. The funds will support the clinical development of Imugene's immuno-oncology pipeline.

Overview and future outlook for Imugene

Imugene Limited, a leader in immuno-oncology, is set to receive approximately $11 million from the Australian Government's R&D tax incentive, expected by January 2025. This financial boost will accelerate the clinical development of its diverse pipeline, which includes CAR T cell therapy, B-cell vaccines, and oncolytic virotherapy. Imugene aims to revolutionize cancer treatment by harnessing the immune system, focusing on establishing its therapies as key treatments globally. The company is supported by international experts and is committed to achieving its commercial and clinical objectives, underscoring the importance of financial resources in advancing long-term biotech research.

Executive insights on R&D refund

This R&D tax refund is an important element of our funding strategy and will support our ongoing commitment to advancing our clinical programs. It allows us to continue our work in transforming the cancer treatment landscape through our innovative therapies.